$SLNO

Portnoy Law Firm launches class action lawsuit against $SLNO alleging concealment of safety issues in lead drug DCCR, following 27% stock plunge.

Soleno Therapeutics faces class action lawsuit alleging false statements about DCCR drug safety. Lead plaintiff deadline: May 5, 2026.

Securities class action filed against $SLNO over alleged misstatements about Prader-Willi drug safety risks. Lead plaintiff deadline set for May 5, 2026.

Class action lawsuit filed against $SLNO alleging failure to disclose fluid retention safety concerns in DCCR drug trials, harming investors who bought shares March-November 2025.

Class action lawsuit filed against $ATARA alleging securities fraud over false statements regarding manufacturing issues and ALLELE study deficiencies affecting tabelecleucel approval prospects.

Investors in $SLNO have until May 5, 2026 to join securities lawsuit alleging undisclosed safety issues with DCCR drug candidate.

Halper Sadeh LLC investigates $OGN, $XOMA, $RMAX, $SLNO acquisitions for potential shareholder harm and fiduciary breaches.

Soleno Therapeutics faces class action lawsuit alleging false safety disclosures about DCCR drug candidate for Prader-Willi syndrome.

Soleno Therapeutics faces class action lawsuit over allegedly undisclosed fluid retention safety issues with DCCR drug candidate during March-November 2025 period.

Soleno Therapeutics faces class action lawsuit over safety concerns and inflated metrics for flagship drug VYKAT™ XR. Stock plunged 27% following August short report and November earnings disappointment.

Hagens Berman files securities class action against $SLNO alleging concealed safety risks and inflated metrics for hyperphagia drug VYKAT XR. Stock crashed 27% following August activist report and November earnings miss.

Soleno Therapeutics faces securities fraud lawsuit alleging undisclosed DCCR safety risks. Investors must file by May 5, 2026.

Rosen Law Firm files securities class action against biopharmaceutical company Aldeyra Therapeutics, alleging false statements. Lead plaintiff deadline: May 29, 2026.

Soleno Therapeutics faces securities litigation alleging undisclosed DCCR safety risks during March-November 2025. Lead plaintiff deadline: May 5, 2026.

Rosen Law Firm filed securities class action against Trip.com over alleged false statements on regulatory risks. Investors have until May 11, 2026 to become lead plaintiffs.

Class action lawsuit filed against $SLNO for alleged misstatements about diazoxide choline safety and efficacy. Lead plaintiff deadline: May 5, 2026.

Rosen Law Firm urges Corcept Therapeutics investors with losses exceeding $100K to join securities class action before April 21, 2026 deadline over alleged FDA application misrepresentations.

Rosen Law Firm alerts $SLNO investors of May 5, 2026 deadline in securities class action alleging false statements about DCCR drug candidate safety risks.

Aquestive Therapeutics faces class action lawsuit alleging securities fraud over false FDA approval statements and concealed anaphylaxis product risks.

Four firms face securities fraud lawsuits alleging operational and financial misstatements. Lead plaintiff deadlines: May 5-8, 2026.